Soligenix Inc. (NASDAQ: SNGX) announced it will apply for funding from the Coalition for Epidemic Preparedness Innovations to develop a vaccine for Bundibugyo virus, with applications due June 12, 2026.

The Princeton, New Jersey-based biopharmaceutical company will collaborate with Dr. Axel Lehrer from the University of Hawaii at Manoa on the application. The team previously developed bivalent and trivalent thermostable vaccines against Ebola virus, Sudan virus and Marburg virus using the CoVaccine HT adjuvant.

According to the press release, these vaccines demonstrated thermostability, immunogenicity and efficacy in non-human primates. The vaccines showed up to 100% protection in non-human primates and maintained stability for at least two years at temperatures of 40 degrees Celsius.

"Our filovirus vaccines have demonstrated broad and robust immune responses in mice and up to 100% protection in non-human primates," stated Dr. Lehrer. "A single-vial subunit vaccine that can be shipped at ambient temperatures and then needs to only be reconstituted with sterile water immediately prior to use has the potential to improve vaccination efforts globally."

The Bundibugyo virus outbreak in the Democratic Republic of Congo and Uganda has resulted in 65 confirmed deaths and 397 confirmed cases as of June 4, 2026. The World Health Organization declared it a Public Health Emergency of International Concern on May 16, 2026.

CEPI has committed $3.6 billion in investments since its launch, working with over 30 investors and 470 global research, development and manufacturing partners. Currently, no approved vaccines exist for Sudan, Bundibugyo or Marburg viruses.

The company's ThermoVax platform technology has been used to thermostabilize vaccines for ricin toxin, filoviruses and COVID-19. Soligenix received Orphan Drug Designation from the FDA for prevention and post-exposure prophylaxis against Sudan Ebolavirus and Marburg virus infection.